Patterns of change in nesiritide use in patients with heart failure: How hospitals react to new information

JACC: Heart Failure

Volumn 1, Issue 4, 2013, Pages 318-324

  Partovian, Chohreh ^a,b   Li, Shu Xia ^b   Xu, Xiao ^a,b   Lin, Haiqun ^b,c   Strait, Kelly M ^b   Hwa, John ^a   Krumholz, Harlan M ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Drug use; Heart failure; Hospital; Organizational learning; Practice patterns; Response to new evidence

Indexed keywords

NESIRITIDE;

ARTICLE; COMORBIDITY; DRUG USE; HEART FAILURE; HOSPITAL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RURAL AREA; STANDARDIZATION; URBAN AREA;

DRUG USE; HEART FAILURE; HOSPITAL; ORGANIZATIONAL LEARNING; PRACTICE PATTERNS; RESPONSE TO NEW EVIDENCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG UTILIZATION; HEART FAILURE; HOSPITALIZATION; HOSPITALS; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 84881524781     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.04.005     Document Type: Article

References (24)

1. Bradford W.D., Chen J., Krumholz H.M. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics 1999, 15:257-268.
2. Peacock W.F., Holland R., Gyarmathy R., et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. JEmerg Med 2005, 29:243-252.
3. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
4. Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
5. Braunwald E., Burnett J.C., Colucci W.S., et al. Natrecor Advisory Panel Report. In: Panel of Cardiology Experts Provides Recommendations to Scios Regarding Natrecor. Healthcare Professional Letter 2005, Scios, Fremont, CA.
6. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365:32-43.
7. Hauptman P.J., Schnitzler M.A., Swindle J., Burroughs T.E. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006, 296:1877-1884.
8. Elixhauser A., Steiner C., Harris D.R., Coffey R.M. Comorbidity measures for use with administrative data. Med Care 1998, 36:8-27.
9. Normand S.L.T., Shahian D.M. Statistical and clinical aspects of hospital outcomes profiling. Stat Sci 2007, 22:206-226.
10. Jones B.L., Nagin D.S. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Soc Methods Res 2007, 35:542-571.
11. Group-Based ModelingofDevelopment 2005, Harvard University Press, Cambridge, MA. D.S. Nagin (Ed.).
12. Team R. R: a language and environment for statistical computing 2010, R Foundation for Statistical Computing, Vienna, Austria.
13. Bradley E.H., Curry L.A., Spatz E.S., et al. Hospital strategies for reducing risk-standardized mortality rates in acute myocardial infarction. Ann Intern Med 2012, 156:618-626.
14. Curry L.A., Spatz E., Cherlin E., et al. What distinguishes top-performing hospitals in acute myocardial infarction mortality rates? A qualitative study. Ann Intern Med 2011, 154:384-390.
15. Krumholz H.M., Curry L.A., Bradley E.H. Survival after acute myocardial infarction (SAMI) study: the design and implementation of a positive deviance study. Am Heart J 2011, 162:981-987.e9.
16. Nelson E.C., Batalden P.B., Huber T.P., et al. Microsystems in health care: Part 1. Learning from high-performing front-line clinical units. Jt Comm J Qual Improv 2002, 28:472-493.
17. Bradley E.H., Herrin J., Wang Y., et al. Door-to-drug and door-to-balloon times: where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). Am Heart J 2006, 151:1281-1287.
18. Bradley E.H., Holmboe E.S., Mattera J.A., Roumanis S.A., Radford M.J., Krumholz H.M. Aqualitative study of increasing beta-blocker use after myocardial infarction: why do some hospitals succeed?. JAMA 2001, 285:2604-2611.
19. Fonarow G.C., Heywood J.T., Heidenreich P.A., Lopatin M., Yancy C.W. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007, 153:1021-1028.
20. Burns L.R., Wholey D.R. Adoption and abandonment of matrix management programs: effects of organizational characteristics and interorganizational networks. Acad Manage J 1993, 36:106-138.
21. Rogers E. Diffusion of Innovations 1995, Free Press, New York, NY.
22. Young G.J., Charns M.P., Shortell S.M. Top manager and network effects on the adoption of innovative management practices: a study of TQM in a public hospital system. Strat Manage J 2001, 22:935-951.
23. Keenan P.S., Normand S.L., Lin Z., et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008, 1:29-37.
24. Krumholz H.M., Wang Y., Mattera J.A., et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006, 113:1693-1701.